Staphylococcus aureus and Pseudomonas aeruginosa are common nosocomial pathogens responsible for biofilm-associated infections. Proton pump inhibitors (PPI), such as esomeprazole, may have novel antimicrobial properties. The objective of this study was to assess whether esomeprazole prevents sessile bacterial growth and biofilm formation and whether it may have synergistic killing effects with standard antibiotics. The antibiofilm activity of esomeprazole at 0.25 mM was tested against two strains each of S. aureus and P. aeruginosa. Bacterial biofilms were prepared using a commercially available 96-peg-plate Calgary biofilm device. Sessile bacterial CFU counts and biomass were assessed during 72 hours of esomeprazole exposure. The killing activities after an additional 24 hours of vancomycin (against S. aureus) and meropenem (against P. aeruginosa) treatment with or without preexposure to esomeprazole were also assessed by CFU and biomass analyses. P. aeruginosa and S. aureus strains exposed to esomeprazole displayed decreased sessile bacterial growth and biomass (P < 0.001, each parameter). After 72 h of exposure, there was a 1-log 10 decrease in the CFU/ml of esomeprazole-exposed P. aeruginosa and S. aureus strains compared to controls (P < 0.001). After 72 h of exposure, measured absorbance was 100% greater in P. aeruginosa control strains than in esomeprazole-exposed strains (P < 0.001). Increased killing and decreased biomass were observed for esomeprazoletreated bacteria compared to untreated controls exposed to conventional antibiotics (P < 0.001, each parameter). Reduced biofilm growth after 24 h was visibly apparent by light micrographs for P. aeruginosa and S. aureus isolates exposed to esomeprazole compared to untreated controls. In conclusion, esomeprazole demonstrated an antibiofilm effect against biofilm-producing S. aureus and P. aeruginosa.
P roton pump inhibitors (PPI) have been shown to have novel antibacterial properties (9, 15) . Against Helicobacter pylori, benzimadazole PPI have been shown to have direct antimicrobial effects (15) . PPI have also been shown to have other effects on microbiologic activity, including inhibition of urease (12) . In 2005, an in vitro study investigated the antibiofilm properties of PPI benzimidazoles against oral streptococci (10) . The results showed that the additions of omeprazole and lansoprazole had a significant effect on Streptococcus mutans biofilms, a common organism found in the human oral flora. However, antibiofilm effects of PPI on other bacteria have not been well studied.
The two most common nosocomial organisms responsible for catheter-related infections, Pseudomonas aeruginosa and Staphylococcus aureus, have a natural tendency to adhere to catheter surfaces and form biofilms, which prevent eradication of these organisms by the immune system or with antibiotics (16) . Theoretically, prevention of biofilm formation by these bacteria could prevent catheter-related infections among hospitalized patients and lead to a major improvement in the care of these patients. These organisms are associated with multiple mechanisms of antibiotic resistance, making prevention of these infections even more important. In previous studies, we demonstrated that combination therapy may be effective for biofilm-embedded P. aeruginosa infections (4), and clarithromycin may have novel biofilm effects (5) . The objective of this study was to investigate whether the use of esomeprazole prevents biofilm formation in health care-associated pathogens. The specific questions were whether esomeprazole could prevent biofilm formation caused by S. aureus and P. aeruginosa and whether the addition of esomeprazole enhances the in vitro activities of vancomycin and meropenem against biofilm-embedded S. aureus and P. aeruginosa, respectively.
MATERIALS AND METHODS
Bacterial strains and culture conditions. Laboratory strains of mucoid P. aeruginosa (ATCC 700888) and mucoid S. aureus (ATCC 29213) as well as two clinical bloodstream isolates of P. aeruginosa and S. aureus (one each) obtained from a central venous catheter were used for all experiments. All isolates were stored in Cryocare vials (Key Scientific Products, Round Rock, TX) at Ϫ80°C. Fresh isolates were subcultured at least twice on 5% blood agar plates (Hardy Diagnostics, Santa Maria, CA) for 24 h at 35°C prior to each investigation. An inoculum of approximately 10 6 CFU/ml was used in every experiment. The inoculum was prepared from an overnight culture grown in broth, diluted accordingly based on the absorbance at 630 nm and verified subsequently by quantitative culture by direct agar plating onto Mueller-Hinton (MH) plates. Colony counts were obtained from plates containing 30 to 300 colonies.
Antimicrobial agents and proton pump inhibitors. A stock solution of esomeprazole (Astra Zeneca) at 0.25 mM was prepared according to the manufacturer's directions in tryptic soy broth (TSB). Stock solutions of meropenem at 30 g/ml (Astra Zeneca) in saline and vancomycin at 20 g/ml (Sigma, St. Louis, Mo) in saline (9% NaCl) were prepared according to the respective manufacturer's directions.
Biofilm batch culture technique and experimental plan. Biofilms were prepared using a commercially available biofilm reactor consisting of 96 independent pegs mounted on the inside lid of a 96-well microtiter plate (Calgary biofilm device [CBD]; Innovotech, Inc.) (1) . Single-strain biofilms were grown by incubating at 37°C the CBD peg lids in microtiter plates containing an inoculum of either P. aeruginosa or S. aureus (10 6 cells/ml) for up to 72 h in a heated, shaking incubator (Shake N Bake hybridization oven; Boekel Scientific, Feasterville, PA) with or without the addition of esomeprazole at 0.25 mM. All experiments were performed at least in triplicate.
PPI biofilm prevention: experimental plan. In one series of experiments, pegs were removed at 2 h, 4 h, 6 h, 24 h, 48 h, and 72 h by using sterile forceps, washed for 1 min using 200 l of 0.9% saline, placed into 200 l of recovery medium (MH broth), and sonicated on high for 8 min to remove adherent bacteria. Serial dilutions of the bacterial suspension were prepared in saline (0.9% NaCl), directly plated on MH agar plates, and counted after overnight incubation at 37°C. To assess the quantitative determination of biomass formation, a colorimetric assay adapted from the method of O'Toole et al. was used (11) . Additional pegs were removed at 2 h, 4 h, 6 h, 24 h, 48 h, and 72 h by using sterile forceps and washed for 1 min using 200 l of 0.9% saline. Pegs were then placed into a solution of 0.1% crystal violet for 15 min. Pegs were then removed using sterile forceps and washed for an additional minute using 200 l sterile of the 0.9% saline to remove nonstained crystal violet. The attached dye was reeluted into MH broth with 95% ethanol, and the absorbance at 580 nm was determined using a spectrophotometer (PowerWave x Select; Bio-Tek Instruments, Inc., Winooski, VT). Uninoculated medium was used as a negative control and served as the blank for all absorbance readings.
PPI adjunctive therapy for biofilm-embedded bacteria. In another series of experiments, S. aureus and P. aeruginosa biofilms were grown for 72 hours in the CBD as described above with or without the addition of esomeprazole at 0.25 mM. After this time, sessile bacteria were challenged with either vancomycin (S. aureus biofilms) or meropenem (P. aeruginosa biofilms) by transferring the CBD peg lids to a 96-well antibiotic challenge plate. CFU on the CBD pegs were assessed by quantitative culture, and biomass after 24 h of antibiotics exposure was assessed as described above.
Microscopic analysis. Microscopic analysis of the biofilms was performed using microfluidic channels controlled by an airtight interface between inflow and outflow ports connected to a pneumatic continuous displacement pump at a shear flow rate of 0.8 dyne/cm 2 (BioFlux Controller, Fluxion Biosciences, South San Francisco, CA). The viewing angle allowed for the visualization of biofilm growth by using an inverted light microscope (EVOS; Advanced Microscopy Group, Bothell, WA). Biofilms of S. aureus and P. aeruginosa were visualized at ϫ20 after 24 h growth with or without the addition of esomeprazole at 0.25 mM.
Analysis. The CFU/ml and spectrophotometer results over time were compared in isolates exposed or not exposed to esomeprazole by using a two-way analysis of variance (ANOVA) with repeated measures. A oneway ANOVA was used to compare CFU/ml and spectrophotometry readings between isolates based on the exposure to esomeprazole with or without standard antibiotics after 24 h of exposure. A P value of less than 0.05 was considered significant (SAS Institute, Cary, NC).
RESULTS
Esomeprazole-treated bacteria displayed decreased sessile bacterial growth and biomass. P. aeruginosa and S. aureus strains exposed to esomeprazole displayed decreased sessile bacterial growth and biomass ( Fig. 1 ) (P Ͻ 0.001, each). After 72 h of were observed in isolates exposed to esomeprazole at 0.25 mM (P Ͻ 0.001). Significantly decreased biomass was observed in sessile P. aeruginosa exposed to esomeprazole (P Ͻ 0.001). Results represent one clinical and one laboratory mucoid strain for each species, with experiments performed in triplicate for each strain. ESO, esomeprazole. exposure, the log 10 CFU/ml of P. aeruginosa in control strains was 8.5 Ϯ 0.03 CFU/ml (mean Ϯ standard deviation), compared to 7.5 Ϯ 0.07 CFU/ml in esomeprazole-exposed strains (P Ͻ 0.001). After 72 h of exposure, the log 10 CFU/ml of S. aureus in control strains was 8.9 Ϯ 0.18 CFU/ml, compared to 7.7 Ϯ 0.11 CFU/ml in esomeprazole-exposed strains (P Ͻ 0.001).
Measured absorbance was significantly higher at all time points sampled for P. aeruginosa strains (average optical density [OD], 0.49) than for S. aureus strains (average OD, 0.22). After 72 h of exposure, measured absorbance was 100% greater in P. aeruginosa control strains (OD, 0.62 Ϯ 0.011) than for esomeprazole-exposed strains (OD, 0.35 Ϯ 0.024; P Ͻ 0.001). However, there was no significant difference in absorbance after 72 h of exposure between S. aureus control strains (OD, 0.23 Ϯ 0.02) and esomeprazole-exposed strains (OD, 0.21 Ϯ 0.010; P Ͼ 0.05).
Increased killing of sessile bacteria and decreased biomass were observed in esomeprazole-treated bacteria given conventional antibiotics. Increased killing and decreased biomass were observed for esomeprazole-treated bacteria compared to untreated controls exposed to conventional antibiotics ( Fig. 2 ; P Ͻ 0.001, each). After 24 h of exposure, the P. aeruginosa CFU/ml decreased from 9.0 Ϯ 0.059 CFU/ml in controls to 8.2 Ϯ 0.51 in meropenem-exposed isolates, to 7.6 Ϯ 0.27 in esomeprazoletreated patients, to 6.6 Ϯ 0.13 in isolates exposed to meropenem and esomeprazole (P Ͻ 0.001). After 24 h of exposure, the S. aureus CFU/ml decreased from 9.1 Ϯ 0.14 CFU/ml in controls to 6.9 Ϯ 0.48 in vancomycin-exposed isolates, to 6.5 Ϯ 0.24 in esomeprazole-treated patients, to 5.0 Ϯ 1.6 in isolates exposed to vancomycin and esomeprazole (P Ͻ 0.001).
After 24 h of exposure, P. aeruginosa absorbance decreased from 0.64 Ϯ 0.029 in controls to 0.46 Ϯ 0.083 in meropenemexposed isolates, to 0.43 Ϯ 0.052 in esomeprazole-treated patients, to 0.33 Ϯ 0.041 in isolates exposed to meropenem and esomeprazole (P Ͻ 0.001). After 24 h of exposure, the S. aureus absorbance decreased from 0.54 Ϯ 0.038 in controls to 0.48 Ϯ 0.042 in vancomycin-exposed isolates, to 0.44 Ϯ 0.042 in esomeprazole-treated patients, to 0.25 Ϯ 0.0058 in isolates exposed to vancomycin and esomeprazole (P Ͻ 0.001).
Light micrographs of P. aeruginosa and S. aureus exposed to 24 h of esomeprazole compared to controls. Light micrographs of P. aeruginosa and S. aureus cells exposed to 24 h of esomeprazole compared to controls are shown in Fig. 3 . Reduced biofilm growth after 24 h was visibly apparent in the P. aeruginosa and S. aureus isolates exposed to esomeprazole compared to the untreated controls.
DISCUSSION
Biofilm-related infections are an important cause of health care-associated infections. Despite significant research involving antibiotic-impregnated catheters, other coated catheters, and other novel techniques, biofilm-related infections are important causes of device-related and catheter-related infections (2) . Biofilm-embedded bacteria are challenging to treat, as they display tolerance to antibiotic killing activity and the host immune system (6, 8) . Traditional antibiotics were developed to kill planktonic bacteria and often have a limited effect on the killing of sessile bacteria encased within a biofilm. In addition, antimicrobial resistance development is common in sessile FIG 2 Effects of esomeprazole, as adjunctive therapy with standard antibiotics, on CFU and biomass for P. aeruginosa and S. aureus. Significantly decreased CFU/ml counts of sessile P. aeruginosa and S. aureus were observed for isolates exposed to esomeprazole at 0.25 mM and antibiotics, compared to cells exposed to antibiotics alone. bacteria. For these reasons, there is an urgent need to develop nonantimicrobial treatment strategies to prevent or treat biofilm-associated infections (7) .
In this study, we demonstrated that the PPI esomeprazole displays an antibiofilm effect, as demonstrated by decreased biomass and morphological antibiofilm changes associated with the addition of esomeprazole against two common biofilm-producing health care-associated pathogens. This study builds on the findings of Nguyen et al., who investigated the use of benzimidazole PPI against biofilm-embedded Streptococcus mutans (10) . In that study, lansoprozole or omeprazole was used to test the antibiofilm effect of S. mutans in a number of different in vitro models. Lansoprazole at 0.1 mM markedly inhibited biofilm glycolysis. The study concluded that benzimidazole PPI may be useful against oral biofilm-producing bacteria. This study extends these previous findings by demonstrating an antibiofilm effect in the health care-associated pathogens P. aeruginosa and S. aureus.
Sambanthamoorthy et al. recently identified a novel benzimidazole that inhibits bacterial biofilm formation (14) . In their study, a small-molecule screen identified a benzimidazole that prevented biofilm formation in multiple bacterial pathogens, including S. aureus and P. aeruginosa. Using a colorimetric assay similar to our study, a greater-than-50% decrease in biomass was observed in isolates preexposed to the benzimidazoles identified in the screening procedure. Using a catheter infection model, coating the surface of the catheter with ABC-1, the most potent antibiofilm benzimidazole, significantly reduced biofilm formation. Interestingly, those authors described in their study that omeprazole, the parent compound of esomeprazole, did not possess significant antibiofilm activity under the conditions examined. Whether esomeprazole has antibiofilm properties independent of omeprazole or whether the test conditions of these two experiments differed will require further study. In our study, the colorimetric assay for S. aureus did not indicate a decrease in biomass with the addition of esomeprazole. However, the killing activity of S. aureus was significantly increased with the addition of esomeprazole to meropenem. Morphological changes were apparent in S. aureus exposed to esomeprazole. These discrepancies highlight the importance of multiple experiments to assess antibiofilm properties.
Two interesting hypotheses can be tested in future studies developed based on these results. Despite the ability to coat intravascular catheters with antibiotics, many patients still experience catheter-associated bloodstream infections (13) . A direct study arising from these results here could investigate the use of esomeprazole as a lock solution as an adjunct prevention measure with antimicrobial-coated catheters. The use of proton pump inhibitors has also been implicated as a risk factor for Clostridium difficile infection (3) . It is possible that inhibition of biofilm formation in the gut by commensal bacteria may enhance the ability of C. difficile to penetrate to colonic epithelial cells and cause active disease. Both of these hypotheses will require further study.
This study has many limitations. We chose to use fixed, physiologically relevant concentrations of vancomycin, meropenem, and esomeprazole. Future dose-response studies will be required to assess if greater killing or a decrease in biomass is possible with different dosing regimens. These studies will also be required to be repeated in other relevant in vitro/in vivo models to confirm these results.
In conclusion, the addition of esomeprazole significantly decreased biomass and enhanced killing of P. aeruginosa and S. aureus by standard antimicrobial agents. Future research should focus on the novel benefits and toxicities associated with these findings.
